Ofatumumab

Information about Ofatumumab

Ofatumumab is a recombinant human monoclonal antibody to CD20 a cell surface antigen found on pre-B and mature B lymphocytes and which is approved for use in resistant chronic lymphocytic leukemia. 

Liver safety of Ofatumumab

Ofatumumab therapy has not been associated with serum enzyme elevations during therapy or to cases of idiosyncratic, clinically apparent liver injury.  However, ofatumumab has potent immunosuppressive activity and its use has been associated with cases of reactivation of inactive or previously resolved hepatitis B which can be severe and can result in fatality.   

Mechanism of action of Ofatumumab

Ofatumumab (oh” fa toom’ ue mab) is a human monoclonal IgG1 antibody to the cell surface antigen CD20 (also known as human B lymphocyte restricted differentiation antigen: Bp35), which is found on mature B cells as well as 90% of neoplastic B cell such as occur in chronic lymphocytic leukemia.  CD20 is not present on pro-B cells, hematopoietic stem cells, normal plasma cells or other normal lymphocytes, circulating cells or tissues.  Engagement of ofatumumab with CD20 leads to B cell lysis and depletion of circulating and tissue B cells for an extended period, up to 6 to 8 months.  There is an accompanying mild decrease in IgM, but no change in IgG or IgA levels. 

FDA approval information for Ofatumumab

Ofatumumab was approved for use in previously treated, resistant chronic lymphocyte leukemia United States in 2009. 

Dosage and administration for Ofatumumab

Ofatumumab is available in liquid solution in single use vials of 100 and 1000 mg (20 mg/mL) under the brand name Arzerra.  The dose and regimen varies by indication, but it is usually given intravenously in 300 to 2000 mg amounts in 28 day cycles. 

Side effects of Ofatumumab

Common side effects include infusion reactions, chills, fever, nausea, diarrhea, fatigue, dyspnea, cough, bronchitis, pneumonia, skin rash, neutropenia and infections.  Less common, but potentially severe side effects include cutaneous reactions (Stevens Johnson syndrome), tumor lysis syndrome, prolonged neutropenia, thrombocytopenia and anemia.  Because of the potential severity of infusion reactions, premedication with antihistamines, acetaminophen and corticosteroids is recommended, and ofatumumab should be administered under close medical observation. 

 

The article on Ofatumumab is a stub. YOU can help Wikimd by expanding it!

Medication resources

Learn more

• Dailymed label info
• Scientific articles

edit 

About WikiMD

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.

Join us: This article is a stub. Help improve Ofatumumab or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.